Table 1 Demographic characteristics and clinical parameters of study population
Parameters | Value |
|---|---|
No. of Patients | 1178 |
Age (years) | 38.8 ± 14.0 |
Male [n(%)] | 633 (53.7) |
BMI (kg.m−2) | 22.9 ± 3.5 |
Smoker [n(%)] | 218 (18.5) |
Drinker [n(%)] | 101 (8.6) |
Primary Glomerular Diseases | |
 IgA [n(%)] | 354 (30.1) |
 MsPGN [n(%)] | 17 (1.4) |
 MCD [n(%)] | 38 (3.2) |
 MN [n(%)] | 162 (13.8) |
 FSGS [n(%)] | 36 (3.1) |
 MPGN [n(%)] | 9 (0.8) |
 Others [n(%)] | 562 (47.7) |
Medication | |
 ACEI or ARB [n(%)] | 576 (48.9) |
 β-blocker [n(%)] | 179 (15.2) |
 CCB [n(%)] | 362 (30.6) |
 α-blocker [n(%)] | 71 (6.0) |
 Statin [n(%)] | 200 (17.0) |
Antihypertensive medication use | |
 0[n(%)] | 347 (29.5) |
 1[n(%)] | 570 (48.4) |
 2[n(%)] | 172 (14.6) |
 3[n(%)] | 78 (6.6) |
 4[n(%)] | 11 (0.9) |
Laboratories | |
 Hemoglobin [g/L] | 124.8 ± 27.6 |
 Albumin [g/L] | 34.5 ± 9.0 |
 Total cholesterol [mmol/L] | 5.3 (4.3,6.9) |
 LDL cholesterol [mmol/L] | 3.2 (2.4,4.4) |
 HDL cholesterol [mmol/L] | 1.2 (1.0,1.5) |
 Triglycerides [mmol/L] | 1.5 (1.0,2.3) |
 Calcium [mg/dL] | 8.8 ± 0.8 |
 Phosphate [mg/dL] | 3.7 ± 0.4 |
 Calcium* Phosphate [mg2/dL2] | 35.3 ± 9.9 |
 iPTH [pmol/L] | 4.9 (3.4,8.5) |
 Uric acid [μmol/L] | 434.0 (346.3522.9) |
 Creatinine [μmol/L] | 97.0 (68.3200.0) |
 Stage 1[n(%)] | 489 (42.4) |
 Stage 2[n(%)] | 231 (19.6) |
 Stage 3[n(%)] | 165 (14.0) |
 Stage 4[n(%)] | 96 (8.1) |
 Stage 5[n(%)] | 197 (16.7) |
 eGFR-EPI (ml/min/1.73m2) | 78.0 (30.0,108.0) |
 eGFR< 60 ml/min/1.73m2 [n(%)] | 458 (38.9) |
 ACR [mg/g] | 302.4 (85.6851.2) |
 ACR ≥ 30 mg/g [n(%)] | 1031 (87.5) |
 cIMT-left [mm] | 0.7 ± 0.2 |
 cIMT-right [mm] | 0.7 ± 0.2 |
 cIMT≥0.9 mm or plaque [n(%)] | 251 (21.3) |
 Left ventricular mass index [g/m2] | 92.1 ± 24.4 |
 Left ventricular hypertrophy [n(%)] | 116 (9.8) |